B+
Bull case
20%
Probability
Target price
$2.30
+39.4% vs current
AIFF
Firefly NeuroscienceBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.40
-15.2% vs current
B-
Bear case
30%
Probability
Target price
$0.55
-66.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+27.4
Score
AI commentary
This is a cautious monitoring name, not a clean momentum long. Primary filings show a legitimate commercial platform and better 2025 revenue, but they also show that liquidity remains the dominant issue, forward visibility is sparse, and recent evidence is mostly financing-related rather than demand-confirming [#10-K-2026-03-31] [#8-K-2026-03-12]. That matches the current deterministic prior, which is neutral with lower evidence quality and low catalyst density versus the earlier, more optimistic baseline.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-30eventMarch financing resale registration and effectiveness window could reset the overhangHigh impact
The March 12, 2026 private placement requires Firefly to file a resale registration statement by April 15, 2026 and use best efforts to obtain effectiveness within 45 days if not reviewed, or 90 days if reviewed. That can improve near-term funding visibility, but it also formalizes a dilution and resale overhang around a $1.50 financing with attached warrants [#8-K-2026-03-12].
2026-06-30catalystBalance-sheet updates will matter more than narrative until going-concern pressure easesHigh impact
The 10-K states there is substantial doubt about the company’s ability to continue as a going concern, with 2025 operating cash outflow of $8.194 million, year-end cash of $2.747 million, and explicit dependence on future equity or debt raises, including a new ATM program and the March private placement. Any evidence that liquidity is not improving would likely weigh on the stock [#10-K-2026-03-31].
2026-12-31catalystCommercial conversion of the Evoke installed base remains the core upside pathHigh impact
The 10-K says the FDA-cleared Evoke System was in active use across more than 85 U.S. clinical sites at December 31, 2025, while 2025 revenue rose to $1.142 million from $0.108 million in 2024. If those deployments convert into recurring subscription and service revenue, AIFF could begin to show a more credible commercialization curve, but visibility is still limited [#10-K-2026-03-31].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology